Recent guideline updates for squamous cell skin cancer add adjuvant cemiplimab as a preferred option for certain patients with very high-risk disease.
Guidelines | Guideline Updates for CSCC: Optimizing Outcomes in High-Risk Patients
Guideline Updates for CSCC: Optimizing Outcomes in High-Risk Patients
Articles
Videos
Systemic therapy for CSCC is evolving toward earlier use, combination and de-escalation strategies, and biomarker-driven personalization to improve outcomes and reduce toxicity.
Multidisciplinary collaboration is essential in managing high-risk CSCC, helping clinicians overcome logistical barriers to deliver coordinated, individualized care.
Advertisement
Advertisement
Trending on AJMC
1
Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD
2
Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo
3
emtelligent Turns Unstructured Clinical Data Into Actionable Insights
4
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
5